You are here: Industry Insights > Catalent

News List

Catalent, J&J Announce COVID-19 Vaccine Candidate Manufacturing Agreement americanpharmaceuticalreview
May 06, 2020
Catalent has announced a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby Catalent’s Biologics business unit will accelerate availability of manufacturing capacity ...
Arcturus, Catalent Partner to Manufacture COVID-19 Vaccine contractpharma
May 05, 2020
The manufacture of LUNAR-COV19 at Catalent’s drug substance biomanufacturing facility in Madison, WI will support human clinical studies.
Catalent Appoints Cell & Gene Therapy President contractpharma
May 04, 2020
Manja Boerman will lead all of Catalent’s cell & gene therapy businesses worldwide.
Catalent, J&J Enter Mfg. Pact for COVID-19 Vax Candidate contractpharma
April 30, 2020
Includes joint investment and tech transfer to prepare for rapid scale-up and cGMP commercial manufacturing at Catalent's Bloomington facility.
Catalent Completes $14M Biologics Packaging Expansion contractpharma
April 24, 2020
Adds 15,000 square feet of packaging infrastructure to biologics and sterile manufacturing at its Bloomington, IN facility.
Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment americanpharmaceuticalreview
March 18, 2020
Catalent welcomed the announcement by Biohaven the U.S. Food and Drug Administration (FDA) has approved its NURTEC? ODT (rimegepant) for the acute treatment of migraine in adults.
Biohaven Wins FDA Approval for NURTEC ODT contractpharma
March 18, 2020
Developed in partnership with Catalent using its Zydis orally disintegrating tablet (ODT) technology.
Bristol-Myers Squibb completes divestment of manufacturing facility in Anagni, Italy worldpharmanews
January 09, 2020
Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its previously announced divestment of its oral solid, biologics, and sterile product manufacturing and ...
Minerva, Catalent Enter Long-Term Commercial Supply Pact contractpharma
September 25, 2019
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on therapies to treat central nervous system (CNS) disorders ...
Catalent Invests $9M in New Clinical Supply Facility contractpharma
September 06, 2019
New 24,257 sq.-ft. facility in San Diego will specialize in services for early-phase clinical trials.